Breaking News - The Fly

Open Search

OCUP

Ocuphire Pharma

$

()

Ocuphire Pharma announces enrollment of first patient in LYNX-2 Phase 3 study

OCUP

4/11/2024 - 10:05am

Ocuphire Pharma announces U.S. commercial launch of RYZUMVI

OCUP , VTRS

4/1/2024 - 07:16am

Ocuphire Pharma price target lowered to $20 from $24 at Alliance Global

OCUP

3/20/2024 - 07:51am

Ocuphire Pharma expects cash to fund operations into mid-2025

OCUP

3/8/2024 - 08:08am

Ocuphire Pharma reports Q4 EPS (21c), consensus (5c)

OCUP

3/8/2024 - 08:08am

Ocuphire Pharma appoints Jayagopal as CSDO, Jhaveri as CFO

OCUP

2/14/2024 - 08:14am

Ocuphire Pharma announces presentation on APX3330

OCUP

2/5/2024 - 08:08am

Ocuphire Pharma files $175M mixed securities shelf

OCUP

1/10/2024 - 17:02pm

Ocuphire Pharma receives FDA agreement under SPA for LYNX-2 Phase 3 trial

OCUP

1/4/2024 - 08:01am

Ocuphire Pharma announces appointment of Schachle as COO

OCUP

11/27/2023 - 08:07am

Ocuphire Pharma expects cash to fund operations into 2025

OCUP

11/13/2023 - 08:13am

Ocuphire Pharma reports Q3 EPS 25c, consensus (22c)

OCUP

11/13/2023 - 08:12am

Ocuphire Pharma announces end-of-phase2 meeting with FDA for APX3330

OCUP

11/2/2023 - 08:11am

Ocuphire Pharma appoints Magrath as CEO, Director

OCUP

11/1/2023 - 08:22am

Viatris and Ocuphire announce FDA approved RYZUMVI to treat mydriasis

VTRS , OCUP

9/27/2023 - 08:04am